Oral tolerance

Immunological Reviews

Volumn 241, Issue 1, 2011, Pages 241-259

  Weiner, Howard L ^a   da Cunha, Andre Pires ^a   Quintana, Francisco ^a   Wu, Henry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anti CD3; Autoimmunity; Mucosal; Therapy; Tolerance; Tregs

Indexed keywords

2 (1'H INDOLE 3' CARBONYL) THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANTIBODY; CD103 ANTIGEN; CD3 ANTIBODY; CD80 ANTIBODY; CD86 ANTIBODY; CHOLERA TOXIN B SUBUNIT; CHOLINERGIC RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 5; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNAJP1; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN; IMMUNOLOGIC AGENT; INSULIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OKT 3; OVALBUMIN; PROBIOTIC AGENT; STAPHYLOCOCCUS SUPERANTIGEN; THYROGLOBULIN; TROPONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ATHEROSCLEROSIS; CD8+ T LYMPHOCYTE; CLONAL ANERGY; COLITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIABETES MELLITUS; EOSINOPHILIA; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE IMMUNITY; LACTOBACILLUS; LIVER; LUNG GRAFT REJECTION; LUPUS VULGARIS; MESENTERY LYMPH NODE; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NERVE INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; STROKE; SYSTEMIC SCLEROSIS; THYROIDITIS;

ADMINISTRATION, ORAL; ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 79954511312     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01017.x     Document Type: Review

References (195)

1. Moog F. The lining of the small intestine. Sci Am 1981;245:154-158; 160, 162 et passiom.
2. Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987;40:153-245.
3. Brandtzaeg P. Development and basic mechanisms of human gut immunity. Nutr Rev 1998;56:S5-S18.
4. Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl. 1997;222:3-9.
5. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331-341.
6. Rescigno M. Intestinal dendritic cells. Adv Immunol 2010;107:109-138.
7. Yoshida M, et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 2006;116:2142-2151.
8. Sheridan BS, Lefrancois L. Intraepithelial lymphocytes: to serve and protect. Curr Gastroenterol Rep 2010;12:513-521.
9. Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 1997;158:3610-3618.
10. Strober W. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 2009;31:377-388.
11. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006;212:256-271.
12. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008;134:392-404.
13. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-259.
14. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004;21:527-538.
15. Mora JR, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314:1157-1160.
16. Gershon RK. A disquisition on suppressor T cells. Transplant Rev 1975;26:170-185.
17. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992;89:421-425.
18. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
19. Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 1998;160:5815-5825.
20. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999;190:229-239.
21. Akbari O, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002;8:1024-1032.
22. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001;2:671-672.
23. Mucida D, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007;317:256-260.
24. Coombes JL, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007;204:1757-1764.
25. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007;204:1765-1774.
26. Sun CM, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007;204:1775-1785.
27. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007;8:1086-1094.
28. Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med 2007;204:1519-1524.
29. Shiokawa A, Tanabe K, Tsuji NM, Sato R, Hachimura S. IL-10 and IL-27 producing dendritic cells capable of enhancing IL-10 production of T cells are induced in oral tolerance. Immunol Lett 2009;125:7-14.
30. Manicassamy S, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010;329:849-853.
31. Matteoli G, et al. Gut CD103+ dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010;59:595-604.
32. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005;106:2375-2381.
33. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ, Curotto de Lafaille MA. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 2005;115:1923-1933.
34. Goubier A, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008;29:464-475.
35. Dubois B, Joubert G, Gomez de Aguero M, Gouanvic M, Goubier A, Kaiserlian D. Sequential role of plasmacytoid dendritic cells and regulatory T cells in oral tolerance. Gastroenterology 2009;137:1019-1028.
36. Nagatani K, et al. Splenic dendritic cells induced by oral antigen administration are important for the transfer of oral tolerance in an experimental model of asthma. J Immunol 2006;176:1481-1489.
37. Worbs T, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med 2006;203:519-527.
38. Rescigno M, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-367.
39. Kraus TA, et al. Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops. J Clin Invest 2005;115:2234-2243.
40. Spahn TW, et al. Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. Eur J Immunol 2001;31:1278-1287.
41. Spahn TW, et al. Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. Eur J Immunol 2002;32:1109-1113.
42. Miyamoto K, et al. The ICOS molecule plays a crucial role in the development of mucosal tolerance. J Immunol 2005;175:7341-7347.
43. Liu L, Kuchroo VK, Weiner HL. B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance. J Immunol 1999;163:2284-2290.
44. Gonnella PA, Chen YH, Waldner H, Weiner HL. Induction of oral tolerization in CD86 deficient mice: a role for CD86 and B cells in the up-regulation of TGF-beta. J Autoimmun 2006;26:73-81.
45. Samoilova EB, Horton JL, Zhang H, Khoury SJ, Weiner HL, Chen Y. CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol 1998;10:491-498.
46. Fukaya T, et al. Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood 2010;116:2266-2276.
47. Park JJ, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010;116:1291-1298.
48. van Wijk F, et al. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. J Immunol 2007;178:6894-6900.
49. Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001;167:4245-4253.
50. Thorstenson KM, Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 2001;167:188-195.
51. Tsuji NM, Mizumachi K, Kurisaki J. Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance. Immunology 2001;103:458-464.
52. Oida T, et al. CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 2003;170:2516-2522.
53. Ochi H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 2006;12:627-635.
54. Gandhi R, Farez MF, Wang Y, Kozoriz D, Quintana FJ, Weiner HL. Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol 2010;184:4620-4624.
55. Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009;182:111-120.
56. Chen ML, Yan BS, Bando Y, Kuchroo VK, Weiner HL. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 2008;180:7327-7337.
57. Chen ML, Yan BS, Kozoriz D, Weiner HL. Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 2009;39:3423-3435.
58. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-644.
59. Nakamura K, et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-842.
60. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009;106:13445-13450.
61. Battaglia M, Roncarolo MG. The Tregs' world according to GARP. Eur J Immunol 2009;39:3296-3300.
62. Oida T, Weiner HL. Overexpression of TGF-beta1 gene induces cell surface localized glucose-regulated protein 78-associated latency-associated peptide/TGF-beta. J Immunol 2010;185:3529-3535.
63. Oida T, Weiner HL. TGF-beta induces surface LAP expression on murine CD4 T cells independent of Foxp3 induction. PLoS ONE 2010;5:e15523.
64. Awasthi A, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007;8:1380-1389.
65. Zhang X, Reddy J, Ochi H, Frenkel D, Kuchroo VK, Weiner HL. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 2006;18:495-503.
66. Chen Y, Inobe J, Weiner HL. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol 1995;155:910-916.
67. Lider O, Santos LM, Lee CS, Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. J Immunol 1989;142:748-752.
68. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005;174:5814-5822.
69. Garside P, Steel M, Liew FY, Mowat AM. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int Immunol 1995;7:501-504.
70. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002;109:719-731.
71. Kriegel MA, Rathinam C, Flavell RA. E3 ubiquitin ligase GRAIL controls primary T cell activation and oral tolerance. Proc Natl Acad Sci USA 2009;106:16770-16775.
72. Ise W, et al. Orally tolerized T cells can form conjugates with APCs but are defective in immunological synapse formation. J Immunol 2005;175:829-838.
73. Mirenda V, et al. Tolerant T cells display impaired trafficking ability. Eur J Immunol 2005;35:2146-2156.
74. Song F, Guan Z, Gienapp IE, Shawler T, Benson J, Whitacre CC. The thymus plays a role in oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 2006;177:1500-1509.
75. Chung Y, Lee SH, Kim DH, Kang CY. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance. J Leukoc Biol 2005;77:906-913.
76. Ju JH, et al. Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis. Immunol Lett 2008;117:16-25.
77. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway CA Jr, Weiner HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388-391.
78. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180.
79. Oida T, Xu L, Weiner HL, Kitani A, Strober W. TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol 2006;177:2331-2339.
80. Wing K, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-275.
81. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007;7:622-632.
82. Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol 2001;13:825-833.
83. Peron JP, et al. Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. J Neuroimmunol 2010;227:10-17.
84. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007;56:2103-2109.
85. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-1208.
86. Ilan Y, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010;107:9765-9770.
87. Wu HY, Center EM, Tsokos GC, Weiner HL. Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 2009;18:586-596.
88. Wu HY, Maron R, Tukpah AM, Weiner HL. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol 2010;185:3401-3407.
89. Sasaki N, et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009;120:1996-2005.
90. Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008;181:6038-6050.
91. Krause I, Blank M, Sherer Y, Gilburd B, Kvapil F, Shoenfeld Y. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 2002;32:3414-3424.
92. Maier E, et al. Induction of immune tolerance by oral IVIG. Int Immunopharmacol 2007;7:351-359.
93. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991;174:791-798.
94. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007;7:650-654.
95. Tran DQ, Shevach EM. Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum Immunol 2009;70:294-299.
96. Hauben E, et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 2008;112:1214-1222.
97. Kerkvliet NI, et al. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 2009;1:539-547.
98. Quintana FJ, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71.
99. Zhang L, et al. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. Invest Ophthalmol Vis Sci 2010;51:2109-2117.
100. Henry EC, Bemis JC, Henry O, Kende AS, Gasiewicz TA. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch Biochem Biophys 2006;450:67-77.
101. Okey AB, Vella LM, Harper PA. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol Pharmacol 1989;35:823-830.
102. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105:9721-9726.
103. Quintana FJ, et al. From the Cover: an endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010;107:20768-20773.
104. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007;104:18169-18174.
105. Chang J-H, Kim Y-J, Han S-H, Kang C-Y. IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur J Immunol 2009;39:1241-1251.
106. Curotto de LaFaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009;30:626-635.
107. Josefowicz SZ, Rudensky A. Control of Regulatory T Cell Lineage Commitment and Maintenance. Immunity 2009;30:616-625.
108. Machado FS, et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006;12:330-334.
109. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschlager M, Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol 2009;183:66-74.
110. Kimura A, et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 2009;206:2027-2035.
111. Sekine H, et al. Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock. Mol Cell Biol 2009;29:6391-6400.
112. Wada Y, Hisamatsu T, Kamada N, Okamoto S, Hibi T. Retinoic acid contributes to the induction of IL-12-hypoproducing dendritic cells. Inflamm Bowel Dis 2009;15:1548-1556.
113. Kawakami Y, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA 2006;103:153-158.
114. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
115. Korn T, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008;105:18460-18465.
116. Apetoh L, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010;11:854-861.
117. Gandhi R, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010;11:846-853.
118. Chmill S, Kadow S, Winter M, Weighardt H, Esser C. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin impairs stable establishment of oral tolerance in mice. Toxicol Sci 2010;118:98-107.
119. Kinoshita H, et al. Breakdown of mucosal immunity in gut by 2, 3, 7, 8-tetraclorodibenzo-p-dioxin (TCDD). Environ Health Prev Med 2006;11:256-263.
120. Kerkvliet NI. AHR-mediated immunomodulation: the role of altered gene transcription. Biochem Pharmacol 2009;77:746-760.
121. Schecter A, Birnbaum L, Ryan JJ, Constable JD. Dioxins: an overview. Environ Res 2006;101:419-428.
122. Kerkvliet NI. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol 2002;2:277-291.
123. van Leeuwen FX, Feeley M, Schrenk D, Larsen JC, Farland W, Younes M. Dioxins: WHO's tolerable daily intake (TDI) revisited. Chemosphere 2000;40:1095-1101.
124. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21:102-116.
125. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411-420.
126. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118.
127. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
128. Maassen CB, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine. 2008;26:2056-2057.
129. Ochoa-Reparaz J, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009;183:6041-6050.
130. Ochoa-Reparaz J, et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 2010;3:487-495.
131. Wen L, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008;455:1109-1113.
132. Atarashi K, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-812.
133. Ivanov II, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-349.
134. Wu HJ, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32:815-827.
135. Walton KL, Galanko JA, Balfour Sartor R, Fisher NC. T cell-mediated oral tolerance is intact in germ-free mice. Clin Exp Immunol 2006;143:503-512.
136. Repa A, et al. Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora. Immunol Lett 2008;117:50-56.
137. Tsuda M, et al. Intestinal commensal bacteria promote T cell hyporesponsiveness and down-regulate the serum antibody responses induced by dietary antigen. Immunol Lett 2010;132:45-52.
138. Yang R, Liu Q, Grosfeld JL, Pescovitz MD. Intestinal venous drainage through the liver is a prerequisite for oral tolerance induction. J Pediatr Surg 1994;29:1145-1148.
139. Watanabe T, et al. A liver tolerates a portal antigen by generating CD11c+ cells, which select Fas ligand+ Th2 cells via apoptosis. Hepatology 2003;38:403-412.
140. Limmer A, et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol 2005;35:2970-2981.
141. May AG, Bauer S, Leddy JP, Panner B, Vaughan J, Russell PS. Survival of allografts after hepatic portal venous administration of specific transplantation antigen. Ann Surg 1969;170:824-832.
142. Hultkrantz S, Ostman S, Telemo E. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology 2005;116:362-372.
143. Safadi R, et al. Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10. J Immunol 2005;175:3577-3583.
144. Luth S, et al. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest 2008;118:3403-3410.
145. Yu S, Nakafusa Y, Flye MW. Portal vein administration of donor cells promotes peripheral allospecific hyporesponsiveness and graft tolerance. Surgery 1994;116:229-234. discussion 34-5.
146. Roelofs-Haarhuis K, Wu X, Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 2004;173:1043-1050.
147. Kim HJ, Hwang SJ, Kim BK, Jung KC, Chung DH. NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor beta, and by clonally deleting antigen-specific T cells. Immunology 2006;118:101-111.
148. Trop S, Samsonov D, Gotsman I, Alper R, Diment J, Ilan Y. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 1999;29:746-755.
149. Ilan Y, et al. Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes. Am J Gastroenterol 2000;95:966-973.
150. Margalit M, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006;101:561-568.
151. Broere F, et al. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol 2008;181:899-906.
152. Keller AC, et al. Hierarchical suppression of asthma-like responses by mucosal tolerance. J Allergy Clin Immunol 2006;117:283-290.
153. van den Berg H, Greuter M, Kraal G, den Haan JM. Different mechanisms regulate CD4(+) T cell independent induction of oral and nasal tolerance of CD8(+) T cells. Immunobiology 2010;215:163-171.
154. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-1035.
155. Ciprandi G, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 2007;28:40-43.
156. Sun JB, Cuburu N, Blomquist M, Li BL, Czerkinsky C, Holmgren J. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 2006;64:251-259.
157. Sun JB, Czerkinsky C, Holmgren J. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand J Immunol 2007;66:278-286.
158. Verhasselt V, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med 2008;14:170-175.
159. Verhasselt V. Oral tolerance in neonates: from basics to potential prevention of allergic disease. Mucosal Immunol 2010;3:326-333.
160. Lonnqvist A, et al. Neonatal exposure to staphylococcal superantigen improves induction of oral tolerance in a mouse model of airway allergy. Eur J Immunol 2009;39:447-456.
161. Lundell AC, et al. Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus. Clin Exp Allergy 2007;37:62-71.
162. Aoyama K, et al. Improved outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to maternal antigens. Blood 2009;113:1829-1833.
163. Miller A, Lider O, Abramsky O, Weiner HL. Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol 1994;24:1026-1032.
164. Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 2001;16:21-28.
165. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83:7443-7446.
166. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-445.
167. Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988;112:364-370.
168. Frenkel D, et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol 2003;171:6549-6555.
169. Frenkel D, et al. Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol 2009;21:817-829.
170. Kurien BT, Asfa S, Li C, Dorri Y, Jonsson R, Scofield RH. Induction of oral tolerance in experimental Sjogren's syndrome autoimmunity. Scand J Immunol 2005;61:418-425.
171. Huibregtse IL, et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007;133:517-528.
172. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 2007;119:952-959.
173. Huibregtse IL, et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009;183:2390-2396.
174. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2010;71:1-11.
175. Takagi H, et al. Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed. Vaccine. 2008;26:6027-6030.
176. Saint-Lu N, et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy. 2009;64:1003-1013.
177. Lavasani S, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 2010;5:e9009.
178. Ando T, et al. Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance. J Allergy Clin Immunol 2007;120:916-923.
179. Rynda A, et al. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol 2008;180:5187-5200.
180. Suzuki H, et al. Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 2008;135:917-925.
181. Kim WU, et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002;46:1109-1120.
182. Yamada Y, et al. Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol 2009;183:237-245.
183. Bresson D, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-1381.
184. Park KS, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol 2009;19:581-589.
185. Koffeman EC, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009;60:3207-3216.
186. Postlethwaite AE, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810-1822.
187. Kapp K, et al. Modulation of systemic antigen-specific immune responses by oral antigen in humans. Eur J Immunol 2010;40:3128-3137.
188. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 1994;152:4663-4670.
189. Kraus TA, Cheifetz A, Toy L, Meddings JB, Mayer L. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:82-88. discussion 1.
190. Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008;1150:190-196.
191. Vickery BP, Burks AW. Immunotherapy in the treatment of food allergy: focus on oral tolerance. Curr Opin Allergy Clin Immunol 2009;9:364-370.
192. Caminiti L, et al. A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. Allergy Asthma Proc. 2009;30:443-448.
193. Ganeshan K, Neilsen CV, Hadsaitong A, Schleimer RP, Luo X, Bryce PJ. Impairing oral tolerance promotes allergy and anaphylaxis: a new murine food allergy model. J Allergy Clin Immunol 2009;123:231-238.
194. Ilan Y, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol 2010;30:167-177.
195. NasVax. NasVax Announces the Success of a Phase 2a Clinical Trial of a New Oral Immunotherapy for Fatty Liver Disease, 2011. Available from.